• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Moves Higher; General Motors Earnings Top Views

    4/23/24 2:31:47 PM ET
    $ABEO
    $GM
    $HIBB
    $JBLU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials
    Get the next $ABEO alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining more than 1% on Tuesday.

    The Dow traded up 0.68% to 38,499.41 while the NASDAQ rose 1.69% to 15,711.94. The S&P 500 also rose, gaining, 1.24% to 5,072.91.

    Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Energy Stocks With Over 3% Dividend Yields

    Leading and Lagging Sectors

    Communication services shares climbed by 2% on Tuesday.

    In trading on Tuesday, materials shares fell by 0.5%.

    Top Headline

    General Motors Company (NYSE:GM) reported better-than-expected earnings for its fiscal first quarter.

    The company posted quarterly sales growth of 7.6% year-on-year to $43.01 billion, beating the analyst consensus estimate of $41.88 billion. Adjusted EPS of $2.62 beat the consensus estimate of $2.14.

    General Motors projects adjusted EPS of $9.00 – $10.00 (prior $8.50 – $9.50) versus consensus of $9.08.

    Equities Trading UP
                           

    • Hibbett, Inc. (NASDAQ:HIBB) shares shot up 19% to $86.26 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.
    • Shares of Oportun Financial Corporation (NASDAQ:OPRT) got a boost, surging 36% to $3.0710 after the company announced preliminary first-quarter total revenue above estimates.
    • Palisade Bio, Inc. (NASDAQ:PALI) shares were also up, gaining 31% to $6.48 after the company entered into a collaboration with Strand Life Sciences.

    Equities Trading DOWN

    • JetBlue Airways Corporation (NASDAQ:JBLU) shares dropped 17% to $6.24 after the company reported first-quarter financial results and issued weak FY24 revenue outlook.
    • Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) were down 54% to $3.3950 after the company announced the FDA issued a Complete Response Letter in response to the company’s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.
    • LKQ Corporation (NASDAQ:LKQ) was down, falling 13% to $42.67 after the company reported a first-quarter earnings miss and cut its FY24 outlook.

    Also Check This Out: Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

    Commodities

    In commodity news, oil traded up 1.8% to $83.36 while gold traded down 0.2% at $2,342.00.

    Silver traded up 0.5% to $27.38 on Tuesday, while copper fell 0.9% to $4.4350.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 rose 1.09%, London's FTSE 100 rose 0.26% while Spain's IBEX 35 Index climbed 1.70% The German DAX gained 1.55% French CAC 40 rose 0.81% while Italy's FTSE MIB Index jumped 1.89%.

    The S&P Global UK PMI composite index climbed to 54.0 in April from 52.8 in the previous month. The HCOB Eurozone composite PMI surged to 51.4 in April from 50.3 a month ago.

    Asia Pacific Markets

    Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index gaining 1.92%, China's Shanghai Composite falling 0.74% and India's S&P BSE Sensex gaining 0.12%.

    The annual inflation rate in Hong Kong fell to 2% in March from 2.1% in the prior month. The HSBC India Composite flash PMI climbed to 62.2 in April versus a final reading of 61.8 in the earlier month. The au Jibun Bank Japan Composite PMI rose to 52.6 in April compared to a final reading of 51.7 a month ago.

    Economics

    • Sales of new single-family houses jumped 8.8% month-over-month to an annualized rate of 693,000 in March, compared to a revised 5.1% decline in February.
    • The S&P Global services PMI fell to 50.9 in April, recording the weakest level in five months and missing market estimates of 52.
    • The S&P Global composite PMI fell to 50.9 in April versus 52.1 a month ago.

    Now Read This: Amazon.com, United Airlines And 2 Other Stocks Insiders Are Selling

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO
    $GM
    $HIBB
    $JBLU

    CompanyDatePrice TargetRatingAnalyst
    JetBlue Airways Corporation
    $JBLU
    2/3/2026$6.00Sell → Neutral
    Citigroup
    General Motors Company
    $GM
    1/29/2026$98.00Hold → Buy
    DZ Bank
    Oportun Financial Corporation
    $OPRT
    1/12/2026$5.50Underweight → Neutral
    Analyst
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    General Motors Company
    $GM
    1/8/2026$98.00Neutral → Overweight
    Piper Sandler
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    LKQ Corporation
    $LKQ
    12/10/2025$39.00Overweight
    Stephens
    General Motors Company
    $GM
    12/8/2025$90.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ABEO
    $GM
    $HIBB
    $JBLU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

    Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation Data presented at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, Sweden Carlsbad, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmac

    2/23/26 8:40:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LKQ Corporation Announces Results for Fourth Quarter and Full Year 2025

    Annual operating cash flow3 of $1.1 billion; free cash flow1,3 of $847 million Returned $116 million of Capital to Shareholders; $40 million of Share Repurchases and $76 million in Cash Dividends in the Fourth Quarter Board of Directors Initiated a Comprehensive Review of Strategic Alternatives to Enhance Shareholder Value 2026 Outlook Provided ANTIOCH, Tenn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) today reported fourth quarter and full year 2025 financial results and 2026 financial outlook. "Throughout 2025, our team relentlessly focused on what we could control, resulting in significant free cash flow generation despite sector headwinds across our g

    2/19/26 7:00:00 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    JetBlue Adds Nonstop Service Between Houston and New York

    Twice-daily flights bring convenient nonstop option between two major cities JetBlue (NASDAQ:JBLU) today announced it will add nonstop service between Houston's George Bush Intercontinental Airport (IAH) and New York's John F. Kennedy International Airport (JFK), once again connecting the two major cities with JetBlue's award-winning service and attractive fares. The route will operate twice daily beginning May 21, offering customers flexible options for their travel. Flights are available for purchase now on jetblue.com and on the JetBlue app. "Houston is an important destination for many travelers, and we're pleased to reintroduce nonstop service between JFK and Houston, giving our cu

    2/18/26 9:00:00 AM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ABEO
    $GM
    $HIBB
    $JBLU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Reuss Mark L sold $38,709,455 worth of shares (480,724 units at $80.52) and exercised 230,058 shares at a strike of $41.47, decreasing direct ownership by 73% to 92,293 units (SEC Form 4)

    4 - General Motors Co (0001467858) (Issuer)

    2/18/26 4:35:51 PM ET
    $GM
    Auto Manufacturing
    Industrials

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, CFO Finley John David converted options into 13,333 shares and sold $6,818 worth of shares (3,896 units at $1.75), increasing direct ownership by 53% to 27,353 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:07:40 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $GM
    $HIBB
    $JBLU
    SEC Filings

    View All

    SEC Form 10-K filed by LKQ Corporation

    10-K - LKQ CORP (0001065696) (Filer)

    2/19/26 4:59:09 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    LKQ Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LKQ CORP (0001065696) (Filer)

    2/19/26 7:33:45 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.

    SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/17/26 4:39:49 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $GM
    $HIBB
    $JBLU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Boneparth Peter bought $206,000 worth of shares (50,000 units at $4.12), increasing direct ownership by 83% to 110,398 units (SEC Form 4)

    4 - JETBLUE AIRWAYS CORP (0001158463) (Issuer)

    11/6/25 5:34:51 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ABEO
    $GM
    $HIBB
    $JBLU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JetBlue Airways upgraded by Citigroup with a new price target

    Citigroup upgraded JetBlue Airways from Sell to Neutral and set a new price target of $6.00

    2/3/26 6:50:03 AM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    General Motors upgraded by DZ Bank with a new price target

    DZ Bank upgraded General Motors from Hold to Buy and set a new price target of $98.00

    1/29/26 6:58:08 AM ET
    $GM
    Auto Manufacturing
    Industrials

    Oportun Financial upgraded by Analyst with a new price target

    Analyst upgraded Oportun Financial from Underweight to Neutral and set a new price target of $5.50

    1/12/26 7:47:46 AM ET
    $OPRT
    Finance: Consumer Services
    Finance

    $ABEO
    $GM
    $HIBB
    $JBLU
    Financials

    Live finance-specific insights

    View All

    LKQ Corporation Announces Results for Fourth Quarter and Full Year 2025

    Annual operating cash flow3 of $1.1 billion; free cash flow1,3 of $847 million Returned $116 million of Capital to Shareholders; $40 million of Share Repurchases and $76 million in Cash Dividends in the Fourth Quarter Board of Directors Initiated a Comprehensive Review of Strategic Alternatives to Enhance Shareholder Value 2026 Outlook Provided ANTIOCH, Tenn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) today reported fourth quarter and full year 2025 financial results and 2026 financial outlook. "Throughout 2025, our team relentlessly focused on what we could control, resulting in significant free cash flow generation despite sector headwinds across our g

    2/19/26 7:00:00 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    Oportun to Report Fourth Quarter 2025 Financial Results on Thursday, February 26, 2026

    SAN MATEO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oportun (NASDAQ:OPRT), a mission-driven financial services company, will release financial results for its fourth quarter 2025 on Thursday, February 26, 2026, after market close. Oportun will host a conference call and earnings webcast to discuss results on Thursday, February 26, 2026, at 5:00 pm ET / 2:00 pm PT. A live webcast of the call will be accessible from Oportun's investor relations website at investor.oportun.com, and a webcast replay of the call will be available for one year. The dial-in number for the conference call is 1-866-604-1698 (toll-free) or 1-201-389-0844 (international). Participants should call in 10 minutes prio

    2/12/26 4:10:00 PM ET
    $OPRT
    Finance: Consumer Services
    Finance

    JetBlue to Participate in Fireside Chat at Barclays 43rd Annual Industrial Select Conference

    JetBlue Airways Corporation (NASDAQ:JBLU) will participate in a fireside chat at the Barclays 43rd Annual Industrial Select Conference on February 18th, 2026 at approximately 10:25 a.m. ET. A live, listen-only webcast of the call will be available on JetBlue's investor relations website at the following web address: http://investor.jetblue.com For those unable to listen to the live webcast, it will also be archived on JetBlue's investor relations website under 'Archived Events & Presentations' following the conference call. About JetBlue JetBlue is New York's Hometown Airline®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando and San Juan. JetBlue c

    2/11/26 4:30:00 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ABEO
    $GM
    $HIBB
    $JBLU
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    'Blue Sky' Reaches New Altitude: JetBlue and United Begin Offering Sales Across Both Airlines

    Starting this week, customers can book Blue Sky itineraries with cash or points and miles directly through JetBlue or United—unlocking broader access and a more seamless booking experience across both airlines. JetBlue (NASDAQ:JBLU) and United Airlines (NASDAQ:UAL) today announced the roll out of the next major customer benefit from their Blue Sky collaboration: beginning this week, travelers can start to purchase eligible itineraries operated by either airline directly on JetBlue.com, United.com and each airline's mobile app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210620738/en/Photo courtesy of JetBlue and United.

    2/10/26 2:00:00 PM ET
    $JBLU
    $UAL
    Air Freight/Delivery Services
    Consumer Discretionary

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $GM
    $HIBB
    $JBLU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oportun Financial Corporation

    SC 13G - Oportun Financial Corp (0001538716) (Subject)

    11/21/24 4:32:50 PM ET
    $OPRT
    Finance: Consumer Services
    Finance

    SEC Form SC 13D filed by Oportun Financial Corporation

    SC 13D - Oportun Financial Corp (0001538716) (Subject)

    11/20/24 4:02:35 PM ET
    $OPRT
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care